Drug Trial Radar · NCT02950051
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
926
Actual
Start
Dec 13, 2016
Primary completion
Feb 29, 2024
Study completion Feb 29, 2024
Sponsor
- Lead sponsor
- German CLL Study GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Janssen-Cilag Ltd.; Hoffmann-La Roche; AbbVie; Stichting Hemato-Oncologie voor Volwassenen Nederland; Nordic CLL Study Group; Swiss Cancer Institute; Cancer Trials Ireland; Israeli CLL Study Group
- First posted
- Oct 31, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate if standard chemoimmunotherapy (FCR, BR) in frontline treatment of physically fit CLL patients without del17p or TP 53 mutation can be replaced by combinations of targeted drugs (Venetoclax, Ibrutinib) with anti-CD20-antibodies (Rituximab, Obinutuzumab), which may induce extremely long lasting remissions.
Conditions
- Chronic Lymphocytic Leukemia
Interventions
FludarabineDrug
Fludarabine i.v.: cycles 1-6: 25 mg/m², d1-3, q28d
CyclophosphamideDrug
Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d
RituximabBiological
Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d
BendamustineDrug
Bendamustine i.v.: cycles 1-6: 90mg/m², d1-2, q28d
VenetoclaxDrug
Venetoclax p.o. (ramp-up: dose escalation until final dose is reached) cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d
ObinutuzumabBiological
Obinutuzumab i.v. cycle 1: 100 mg, d1; 900 mg, d1(2); 1000 mg, d8+15, q28d cycles 2-6: 1000 mg, d1, q28d
IbrutinibDrug
Ibrutinib p.o. cycles 1-12: 420 mg, d1-28, q28d cycles 13-36: 420 mg, d1-28, q28d
Primary outcomes
What the sponsor says the trial is designed to measure.
- Miminimal residual disease (MRD) negativity rate in peripheral blood (PB)Time frame: Month 15
- Progression free survival (PFS)Time frame: anticipated for January 2023 (after 213 events occured and 73 months after the first patient has been randomized
Locations
161 sites in 10 countries. Site status is shown where the registry gives one.
Medizinische Universitaet Wien
Vienna, Austria
Hanusch Hospital
Vienna, Austria
Wilhelminenspital
Vienna, Austria
ZNA Stuivenberg
Antwerp, Belgium
Algemeen Ziekenhuis St. Jan
Bruges, Belgium
Jan Yperman Ziekenhuis
Ieper, Belgium
UZ Gasthuisberg
Leuven, Belgium
AZ Delta
Roeselare, Belgium
Aalborg University Hospital
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark
Rigshospitalet/Copenhagen
Copenhagen, Denmark
Sydvestjysk Sygehus Esbjerg
Esbjerg, Denmark
University Hospital Herlev
Herlev, Denmark
Regionshospitalet Holstebro
Holstebro, Denmark
Odense Universitets Hospital
Odense, Denmark
Sjællands Universitetshospital
Roskilde, Denmark
Vejle Hospital
Vejle, Denmark
Helsinki University Hospital
Helsinki, Finland
Jyväskylä Central Hospital
Jyväskylä, Finland
Oulu University Hospital
Oulu, Finland
Tampere University Hospital
Tampere, Finland
Turku University Hospital
Turku, Finland
Gesundheitszentrum Klinikum St Marien
Amberg, Germany
Onkologische Schwerpunktpraxis Kurfürstendamm
Berlin, Germany
Helios-Klinikum Berlin
Berlin, Germany
ZAHO Bonn
Bonn, Germany
Ev. Diakonie-Krankenhaus gemeinnuetzige GmbH
Bremen, Germany
University Hospital of Cologne
Cologne, Germany
St. -Johannes-Hospital Dortmund
Dortmund, Germany
Gefos Dortmund mbH
Dortmund, Germany
BAG Dresden
Dresden, Germany
Universitaetsklinik Carl Gustav Carus
Dresden, Germany
Marien Hospital Düsseldorf GmbH
Düsseldorf, Germany
St. Georg Klinikum Eisenach GmbH
Eisenach, Germany
Helios Klinikum Erfurt
Erfurt, Germany
St. Antonius-Hospital
Eschweiler, Germany
Universitaetsklinikum Essen
Essen, Germany
Centrum fuer Haematologie und Onkologie Bethanien
Frankfurt, Germany
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Germany
MVZ Onkologische Kooperation Harz, Drs. Tessen/Hoyer/Zahn
Goslar, Germany
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.